[{"orgOrder":0,"company":"Skye Bioscience","sponsor":"ProSciento","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Nimacimab","moa":"CB1","graph1":"Nephrology","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Skye Bioscience \/ ProSciento","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ ProSciento"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"9-delta-Tetrahydrocannabinol-valine-hemisuccinate","moa":"CB receptor","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Skye Bioscience \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Skye Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Skye Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Skye Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"9-delta-Tetrahydrocannabinol-valine-hemisuccinate","moa":"CB receptor","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Skye Bioscience \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Skye Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Nanoemulsion","sponsorNew":"Skye Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Skye Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Nanoemulsion","sponsorNew":"Skye Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Skye Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Novotech","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Nanoemulsion","sponsorNew":"Skye Bioscience \/ Skye Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Skye Bioscience \/ Skye Bioscience"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"CMAX","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Skye Bioscience \/ CMAX Clinical Research","highestDevelopmentStatusID":"6","companyTruncated":"Skye Bioscience \/ CMAX Clinical Research"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Nanoemulsion","sponsorNew":"Skye Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Skye Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Emerald Health Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Skye Bioscience \/ Emerald","highestDevelopmentStatusID":"6","companyTruncated":"Skye Bioscience \/ Emerald"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"SBI-100 OE","moa":"CB1 receptor","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Skye Bioscience \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Skye Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Skye Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Skye Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"SBI-100","moa":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Skye Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Skye Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Skye Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Skye Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Skye Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Acquisition","leadProduct":"Nimacimab","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Skye Bioscience","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0.02,"dosageForm":"Injectable\/Injection","sponsorNew":"Skye Bioscience \/ Skye Bioscience","highestDevelopmentStatusID":"6","companyTruncated":"Skye Bioscience \/ Skye Bioscience"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"5AM Ventures","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"SBI-100","moa":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Skye Bioscience","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0.02,"dosageForm":"Emulsion","sponsorNew":"Skye Bioscience \/ 5AM Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Skye Bioscience \/ 5AM Ventures"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol Valine Hemisuccinate","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Skye Bioscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Nimacimab","moa":"","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Skye Bioscience \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Skye Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"SBI-100","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Skye Bioscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol Valine Hemisuccinate","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Skye Bioscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Skye Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Nimacimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Skye Bioscience \/ Skye Bioscience","highestDevelopmentStatusID":"14","companyTruncated":"Skye Bioscience \/ Skye Bioscience"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Beacon Biosignals","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Nimacimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Skye Bioscience \/ Beacon Biosignals","highestDevelopmentStatusID":"14","companyTruncated":"Skye Bioscience \/ Beacon Biosignals"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Nimacimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Skye Bioscience \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Skye Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Nimacimab","moa":"","graph1":null,"graph2":null,"graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"amount2New":0,"dosageForm":"","sponsorNew":"Skye Bioscience \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Skye Bioscience \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Skye Bioscience

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : RYI-018 (nimacimab) is a negative-allosteric modulating antibody targeting the CB1. It will undergo clinical phase 2 development for the treatment of patients with obesity.

                          Brand Name : RYI-018

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          September 23, 2024

                          Lead Product(s) : Nimacimab

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Nimacimab is a negative-allosteric modulating antibody targeting the CB1. It will undergo clinical phase 2 development for the treatment of patients with obesity.

                          Brand Name : RYI-018

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          August 22, 2024

                          Lead Product(s) : Nimacimab

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The collaboration aims to advance the clinical development of RYI-018 (nimacimab), currently being evaluated in early-stage clinical trials involving patients with obesity.

                          Brand Name : RYI-018

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          July 24, 2024

                          Lead Product(s) : Nimacimab

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase I

                          Recipient : Beacon Biosignals

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : This partnership will incorporate sleep quality and sleep apnea endpoints via the Beacon Platform to better understand the comprehensive impact of Nimacimab on patients with obesity.

                          Brand Name : RYI-018

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          July 24, 2024

                          Lead Product(s) : Nimacimab

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase I

                          Sponsor : Beacon Biosignals

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          05

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Lead Product(s) : Tetrahydrocannabinol Valine Hemisuccinate

                          Therapeutic Area : Ophthalmology

                          Study Phase : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Details : SBI-100 is a cannabinoid receptor type 1 (“CB1”) agonist administered topically onto the eye. It is being evaluated for the treatment of primary open angle glaucoma & ocular hypertension.

                          Brand Name : SBI-100

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 10, 2024

                          Lead Product(s) : Tetrahydrocannabinol Valine Hemisuccinate

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Lead Product(s) : Tetrahydrocannabinol Valine Hemisuccinate

                          Therapeutic Area : Ophthalmology

                          Study Phase : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Details : SBI-100 is a cannabinoid receptor type 1 (“CB1”) agonist administered topically onto the eye. It is being evaluated for the treatment of primary open angle glaucoma & ocular hypertension.

                          Brand Name : SBI-100

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          February 26, 2024

                          Lead Product(s) : Tetrahydrocannabinol Valine Hemisuccinate

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Nimacimab is a negative-allosteric modulating antibody targeting the cannabinoid 1 receptor (CB1). Now it will undergo clinical development for the treatment of patients with obesity and chronic kidney disease.

                          Brand Name : RYI-018

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          December 11, 2023

                          Lead Product(s) : Nimacimab

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : SBI-100 is a cannabinoid receptor type 1 (CB1) agonist administered topically onto the eye. It is being evaluated to lower intraocular pressure and in patients with primary open-angle glaucoma or ocular hypertension.

                          Brand Name : SBI-100

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 28, 2023

                          Lead Product(s) : SBI-100

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Through the acquisition, Skye expand its position as a leading endocannabinoid systemfocused pharmaceutical company by including, Bird Rock's lead asset, nimacimab, a first-in-class peripherally-restricted negative allosteric modulator antibody inhibitor...

                          Brand Name : RYI-018

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          August 21, 2023

                          Lead Product(s) : Nimacimab

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Phase I

                          Recipient : Bird Rock Bio

                          Deal Size : $20.0 million

                          Deal Type : Acquisition

                          blank

                          10

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The net financing will be used to advance Phase 2 of SBI-100 OE, a first-in-class, topically-administered CB1 agonist focused on reducing intraocular pressure related to glaucoma and ocular hypertension.

                          Brand Name : SBI-100

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          August 21, 2023

                          Lead Product(s) : SBI-100

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase I

                          Sponsor : 5AM Ventures

                          Deal Size : $17.0 million

                          Deal Type : Financing

                          blank